New biosimilar aims to match keytruda in fighting advanced melanoma
Disease control
Not yet recruiting
This study compares a new drug, AVT32-DRL_PB (a biosimilar to Keytruda), with Keytruda itself in people with stage IIB/C or III melanoma that has been fully removed by surgery. About 120 adults will receive either the biosimilar or Keytruda every 3 weeks for up to 6 cycles. The g…
Phase: PHASE1 • Sponsor: Alvotech Swiss AG • Aim: Disease control
Last updated May 17, 2026 06:48 UTC